The Fort Worth Press - Frenchman rewarded for lifetime of research into narcolepsy

USD -
AED 3.672497
AFN 63.999779
ALL 81.450006
AMD 370.780248
ANG 1.789884
AOA 918.000056
ARS 1390.840613
AUD 1.388585
AWG 1.8
AZN 1.662111
BAM 1.669697
BBD 2.01454
BDT 122.725158
BGN 1.668102
BHD 0.377651
BIF 2976
BMD 1
BND 1.275896
BOB 6.911331
BRL 4.953896
BSD 1.000226
BTN 94.881811
BWP 13.592996
BYN 2.822528
BYR 19600
BZD 2.011629
CAD 1.35898
CDF 2320.000345
CHF 0.780486
CLF 0.022842
CLP 899.000043
CNY 6.828249
CNH 6.829455
COP 3657.4
CRC 454.73562
CUC 1
CUP 26.5
CVE 94.450038
CZK 20.741702
DJF 177.71947
DKK 6.35999
DOP 59.497237
DZD 132.503944
EGP 53.559813
ERN 15
ETB 156.99975
EUR 0.851315
FJD 2.192099
FKP 0.736618
GBP 0.735294
GEL 2.680266
GGP 0.736618
GHS 11.201473
GIP 0.736618
GMD 72.999777
GNF 8775.000359
GTQ 7.641507
GYD 209.25239
HKD 7.83524
HNL 26.620533
HRK 6.428003
HTG 131.024649
HUF 308.854023
IDR 17334.35
ILS 2.94383
IMP 0.736618
INR 94.910503
IQD 1310
IRR 1314000.000294
ISK 122.680267
JEP 0.736618
JMD 156.725146
JOD 0.708976
JPY 156.791011
KES 129.150408
KGS 87.420505
KHR 4012.49611
KMF 420.000087
KPW 899.999976
KRW 1473.729592
KWD 0.30729
KYD 0.833543
KZT 463.288124
LAK 21979.999597
LBP 89549.999776
LKR 319.671116
LRD 183.875027
LSL 16.659591
LTL 2.95274
LVL 0.60489
LYD 6.350018
MAD 9.25125
MDL 17.233504
MGA 4150.000004
MKD 52.564485
MMK 2099.490131
MNT 3577.850535
MOP 8.070846
MRU 39.969879
MUR 47.030152
MVR 15.454972
MWK 1741.497874
MXN 17.476225
MYR 3.970206
MZN 63.900592
NAD 16.659734
NGN 1375.980226
NIO 36.710145
NOK 9.276455
NPR 151.803598
NZD 1.694859
OMR 0.384745
PAB 1.000201
PEN 3.5075
PGK 4.33875
PHP 61.274984
PKR 278.775056
PLN 3.615095
PYG 6151.626275
QAR 3.643497
RON 4.438098
RSD 100.106587
RUB 74.860877
RWF 1461.5
SAR 3.74998
SBD 8.04211
SCR 13.746323
SDG 600.502199
SEK 9.21049
SGD 1.27325
SHP 0.746601
SLE 24.595095
SLL 20969.496166
SOS 570.999642
SRD 37.45802
STD 20697.981008
STN 21.21
SVC 8.7523
SYP 110.524981
SZL 16.659533
THB 32.513046
TJS 9.381822
TMT 3.505
TND 2.88175
TOP 2.40776
TRY 45.178595
TTD 6.789386
TWD 31.629499
TZS 2604.999907
UAH 43.949336
UGX 3760.987334
UYU 39.889518
UZS 11949.999966
VES 488.942755
VND 26356
VUV 117.651389
WST 2.715189
XAF 560.041494
XAG 0.01327
XAU 0.000217
XCD 2.70255
XCG 1.80265
XDR 0.69563
XOF 559.999499
XPF 102.149792
YER 238.596201
ZAR 16.556335
ZMK 9001.205497
ZMW 18.67895
ZWL 321.999592
  • RBGPF

    0.5000

    63.1

    +0.79%

  • CMSD

    0.1500

    23.28

    +0.64%

  • GSK

    -0.7000

    51.61

    -1.36%

  • VOD

    0.3500

    16.15

    +2.17%

  • BCE

    0.1800

    23.96

    +0.75%

  • RYCEF

    0.5500

    16.35

    +3.36%

  • CMSC

    0.0600

    22.88

    +0.26%

  • RIO

    0.1000

    100.58

    +0.1%

  • RELX

    -0.2400

    36.35

    -0.66%

  • NGG

    -1.0600

    88.48

    -1.2%

  • BTI

    -0.0900

    58.71

    -0.15%

  • JRI

    -0.0100

    12.98

    -0.08%

  • BCC

    -1.1400

    78.13

    -1.46%

  • BP

    -0.9700

    46.41

    -2.09%

  • AZN

    -2.6300

    184.74

    -1.42%

Frenchman rewarded for lifetime of research into narcolepsy
Frenchman rewarded for lifetime of research into narcolepsy / Photo: © AFP

Frenchman rewarded for lifetime of research into narcolepsy

Emmanuel Mignot is one of the world's leading experts on narcolepsy, a sleep disorder that he finds both "strange" and "fascinating."

Text size:

The French-born Mignot has dedicated his life to studying the causes of narcolepsy and shedding light on one of the great biological mysteries -- sleep.

His discovery of the genetic and molecular causes of the disorder led to his receiving a prestigious Breakthrough Prize on Thursday along with Japan's Masashi Yanagisawa, who made related findings around the same time.

Because of their discoveries, new treatments for narcolepsy -- which causes people to suddenly fall asleep -- and other sleep disorders are being developed.

About one in every 2,000 people suffers from narcolepsy. Some may experience catalepsy -- a sudden trance-like state.

"I am quite proud because what I have discovered is making an enormous difference for my patients," Mignot said in a telephone interview with AFP. "It's the best reward that one could receive."

The 63-year-old Mignot is a sleep researcher at Stanford University in California.

Thirty years ago, when he was a medical student, Mignot fulfilled his military service requirements in France by coming to Stanford to study a French-made drug that was being used to treat narcolepsy.

At the time, he said, the disease was "virtually unknown" and no one was actively studying it.

He became "completely fascinated."

"I told myself it's incredible, this disease, people fall asleep all the time, we have no idea why, and if we could discover the cause we might understand something new about sleep."

Stanford was already home to a renowned sleep center and its laboratory housed narcoleptic dogs, which Mignot began studying in an effort to find a genetic cause of the disease.

Genome sequencing was very primitive at that time and "everybody told me I was crazy," said Mignot, who currently has an adopted narcoleptic dog called Watson.

"I thought it would take a few years and it ended up taking 10."

In 1999, Mignot found a mutation in the genome of narcoleptic dogs. It was located on membrane receptors in the brain that respond to molecules outside the cell, similar to a lock and a key.

- 'Remake a key' -

The Japanese scientist Yanagisawa, meanwhile, had been studying orphan receptors -- receptors of unknown function -- in mice.

He discovered that a molecule that he named orexin binds to the same receptor Mignot detected as abnormal in dogs.

Mice who were deprived of orexin developed narcolepsy.

Mignot immediately began research on human subjects and found that orexin levels in the brain of narcolepsy patients were zero.

Normally, the molecule is produced in great quantities during the day, especially in the evening, allowing one to fight fatigue.

"You don't make a discovery like this twice in your life," Mignot said. "We found the cause of a disease.

"The advantage, is that we can remake a key," he said, referring to orexin.

For the moment, most patients are treated with a combination of powerful sedatives to help them sleep more soundly and amphetamines to keep them awake during the day.

Mignot said tests using a drug that mimics orexin have been "really miraculous."

Patients are fully awake and "transformed."

The challenge is to develop the right dose to be delivered at the right time.

Several companies, including Takeda of Japan, are working on it, and drugs could be authorized in the next few years.

They could be applied to other patients -- people suffering from depression, for example -- who have difficulty waking up, or to those in a coma.

Mignot meanwhile is studying whether narcolepsy may be caused by a flu virus.

The body's immune system may be confusing a flu virus with the cells that produce orexin and T-cells that fight infection are attacking them as a result.

"I've become interested in how the immune system works in the brain," a field he said is "beginning to explode."

As for sleep, Mignot remains fascinated by it even if he has uncovered one of the great mysteries.

"What is it that sleep does that it is so important that we have to do it every day?" he asked. "It's true that we still don't know."

T.Harrison--TFWP